Introduction: The cobas m 511 integrated hematology analyzer conducts a complete blood count (CBC), white blood cell (WBC) differential, reticulocyte count, and nucleated red blood cell count using automated digital microscopy. This multicenter study validated the analytical performance of the cobas m 511 system.
Methods: Repeatability, reproducibility, carryover, mode-to-mode comparison, cytomorphology, WBC clinical sensitivity, and method comparison were analyzed at four clinical sites using residual whole blood clinical samples (n = 2546) and fresh whole blood from healthy volunteers (n = 480). For WBC clinical sensitivity, the cobas m 511 system automated CBC and WBC differential, system flags, cobas m 511 images, and stained cobas m 511 slides were compared with manual microscopy. Sysmex XN analyzers were used for interinstrument method comparison.
Results: Repeatability and reproducibility results showed low variability. There was no significant sample carryover and no difference between open/closed modes. The overall percentage agreement of morphology assessments with manual microscopy (n = 163 samples) was 95.6% for cobas m 511 images and 95.7% for cobas m 511 slides. The sensitivity and specificity for detecting distributional and/or morphological abnormalities were 94.4% and 74.6% for cobas m 511 automated differential, and 95.9% and 73.3% for cobas m 511 image assessment, compared with a manual 400-cell reference differential (n = 439 samples). Some discordance was seen for monocytes and basophils. Correlations between cobas m 511 and Sysmex XN system data were very good (Pearson's R ≥ 0.95 for most CBC parameters).
Conclusion: The cobas m 511 system performs robustly in the clinical laboratory and is suitable for routine clinical use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijlh.12903 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinically validated HPV assays offer comparable long-term safety in primary cervical cancer screening: A 9-year follow-up of a population-based screening cohort.
Int J Cancer
February 2025
Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Molecular testing for human papillomaviruses (HPV) is gradually replacing cytology in cervical cancer screening. In this longitudinal population-based cohort study, 4140 women 20 to 64 years old attending organized screening were tested at baseline by five different screening methods and followed for 9 years. To assess long-term safety, the cumulative risks of CIN2+/CIN3+ were estimated after a negative baseline result obtained by conventional cytology and four clinically validated HPV assays: Hybrid Capture 2 (hc2), RealTime High Risk HPV assay (RealTime), cobas 4800 HPV Test (cobas_4800), and Alinity m HR HPV (Alinity).
View Article and Find Full Text PDF[Method comparison between two hemostasis analyzers: STA R Max and Cobas t 511].
Ann Biol Clin (Paris)
September 2024
Article Synopsis
- The STA R Max3 and Cobas t511 are automated hemostasis analysers used for various coagulation tests, using mechanical and optical detection methods respectively.
- In tests on fresh plasma samples without interference, both analysers showed good agreement for PT, APTT, fibrinogen, and factor II, while factor V and D-dimers had lower agreement but no clinical consequences.
- For hemolysed samples, the analysers yielded acceptable results for PT, fibrinogen, and D-dimers, but displayed discordance for APTT; the STA R Max3 performed better with highly lipemic samples.
Prevalence of HBV genotypes among patients attending Moi Teaching and Referral Hospital liver clinic.
PLoS One
July 2024
Department of Biochemistry and Clinical Chemistry, School of Medicine, Moi University, Eldoret, Kenya.
Hepatitis B virus (HBV) belongs to the genus Orthohepadnavirus, of Hepadnaviridae family, smallest human deoxyribonucleic acid (DNA) virus with 3200 bp in a partially double-stranded circular DNA. Globally, about 2 billion people are infected with over 65 million of the chronically infected residing in Africa. Ten HBV genotypes (A-J) have been reported across the globe.
View Article and Find Full Text PDFValue of a catch-up HPV test in women aged 65 and above: A Danish population-based nonrandomized intervention study.
PLoS Med
July 2023
University Research Clinic for Cancer Screening, Department of Public Health Programmes, Randers Regional Hospital, Randers, Denmark.
Background: High-risk human papillomavirus (HPV) test is replacing cytology as the primary cervical cancer screening test due to superior sensitivity, but in most countries women ≥65 years have never had an HPV test despite they account for around 50% of cervical cancer deaths. We explored the effect of a catch-up HPV test among 65- to 69-year-old women without previous record of HPV-based screening.
Methods And Findings: This population-based nonrandomized intervention study (quasi-experimental design) included Danish women aged 65 to 69 with no record of cervical cancer screening in the last ≥5.
Clinical characteristics of familial dysalbuminemic hyperthyroxinemia in Chinese patients and comparison of free thyroxine in three immunoassay methods.
Front Endocrinol (Lausanne)
March 2023
Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Objective: Familial dysalbuminemic hyperthyroxinemia (FDH) has not been thoroughly studied in the Chinese population to date. The clinical characteristics of FDH in Chinese patients were summarized, and the susceptibility of common free thyroxine (FT4) immunoassay methods was evaluated.
Methods: The study included 16 affected patients from eight families with FDH admitted to the First Affiliated Hospital of Zhengzhou University.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!